Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

被引：57

作者：

Chang, H

Stewart, AK

Qi, XY

Li, ZH

Yi, QL

Trudel, S

机构：

[1] Univ Toronto, Princess Margaret Hosp, Dept Hematol Lab, Univ Hlth Network,Mclaughlin Ctr Mol Med, Toronto, ON M5G 2M9, Canada

[2] Univ Toronto, Princess Margaret Hosp, Dept Lab Med & Pathobiol, Univ Hlth Network,Mclaughlin Ctr Mol Med, Toronto, ON M5G 2M9, Canada

[3] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Univ Hlth Network,Mclaughlin Ctr Mol Med, Toronto, ON M5G 2M9, Canada

[4] Univ Toronto, Princess Margaret Hosp, Dept Biostat, Univ Hlth Network,Mclaughlin Ctr Mol Med, Toronto, ON M5G 2M9, Canada

来源：

BLOOD | 2005年 / 106卷 / 01期

关键词：

D O I：

10.1182/blood-2005-01-0033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). Because t(4;14) uniquely results in fibroblast growth factor receptor 3 (FGFR3) expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3, and its expression was correlated with the t(4;14) status. FISH detected t(4;14) in 16 (19 %) of 85 MM patient specimens, and immunocytochemistry detected aberrant FGFR3 expression in 13 (15 %). Twelve (75 %) t(4;14)positive cases expressed FGFR3, and 12 (92 %) FGFR3-positive cases harbored a t(4;14). FGFR3 expression and t(4;14)were strongly correlated (P < .001). FGFR3 expression by immunohistochemistry was associated with the immunoglobulin A (IgA) isotype (P < .001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001).

引用

页码：353 / 355

页数：3

共 19 条

[1] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].

Avet-Loiseau, H ;

Facon, T ;

Grosbois, B ;

Magrangeas, F ;

Rapp, MJ ;

Harousseau, JL ;

Minvielle, S ;

Bataille, R .

BLOOD, 2002, 99 (06) :2185-2191

[2] Chromosome translocations in multiple myeloma [J].

Bergsagel, PL ;

Kuehl, WM .

ONCOGENE, 2001, 20 (40) :5611-5622

[3] Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma [J].

Bergsagel, PL ;

Chesi, M ;

Nardini, E ;

Brents, LA ;

Kirby, SL ;

Kuehl, WM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13931-13936

[4] The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant [J].

Chang, H ;

Sloan, S ;

Li, D ;

Zhuang, LH ;

Yi, QL ;

Chen, CI ;

Reece, D ;

Chun, K ;

Stewart, AK .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :64-68

[5] The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts [J].

Chesi, M ;

Nardini, E ;

Lim, RSC ;

Smith, KD ;

Kuehl, WM ;

Bergsagel, PL .

BLOOD, 1998, 92 (09) :3025-3034

[6] Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].

Chesi, M ;

Nardini, E ;

Brents, LA ;

Schrock, E ;

Ried, T ;

Kuehl, WM ;

Bergsagel, PL .

NATURE GENETICS, 1997, 16 (03) :260-264

[7]

CHESI M, 2001, BLOOD, V96, P1271

[8] A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma [J].

Dring, AM ;

Davies, FE ;

Fenton, JAL ;

Roddam, PL ;

Scott, K ;

Gonzalez, D ;

Rollinson, S ;

Rawstron, AC ;

Rees-Unwin, KS ;

Li, C ;

Munshi, NC ;

Anderson, KC ;

Morgan, GJ .

CLINICAL CANCER RESEARCH, 2004, 10 (17) :5692-5701

[9] Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].

Fonseca, R ;

Blood, E ;

Rue, M ;

Harrington, D ;

Oken, MM ;

Kyle, RA ;

Dewald, GW ;

Van Ness, B ;

Van Wier, SA ;

Henderson, KJ ;

Bailey, RJ ;

Greipp, PR .

BLOOD, 2003, 101 (11) :4569-4575

[10] Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) [J].

Intini, D ;

Baldini, L ;

Fabris, S ;

Lombardi, L ;

Ciceri, G ;

Maiolo, AT ;

Neri, A .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :362-364

← 1 2 →